Annual Report 2023
Department of Pharmacy
Toshikatsu Kawasaki, Reiko Matsui, Masahito Yonemura, Yasuaki Ryushima, Daisuke Kano, Naoko Kumazawa, Shinya Suzuki, Shinichi Masuda, Kenji Kawasumi, Chihiro Nakada, Misaki Takeno, Akira Shinohara, Takahiro Akita, Ayumi Komuro, Yoshihiro Iwamoto, Sayaka Nakajima, Akiko Hashimoto, Shinya Uozumi, Masaki Tanaka, Kanako Kusuhara, Takashi Igarashi, Wataru Suenaga, Hidetaka Suzuki, Yumiko Seto, Ken Demachi, Asumi Kaneko, Kazuki Sugisaki, Maho Nakamura, Junko Tauchi, Kaho Miura, Mashiro Okunaka, Manami Harada, Kenya Tanimoto, Atsushi Kawanobe, Kaede Baba, Yuma Shibutani, Hiroki Sato
Introduction
The main objectives of the Department of Pharmacy are: (1) To promote clinical studies to create new evidence-based data; (2) To provide chemotherapy based on the most updated evidence-based data; and (3) To pursue patient-centered pharmaceutical care.
Our resident training program started in 2006. In 2023, seven residents joined our department. Presently, we have a total of 20 residents. In addition, our department accepted five trainees from other institutions for our oncology pharmacist training programs in 2023. In 2023, we educated three pharmacy students.
The Department of Pharmacy provides various important services: controlling inventory, dispensing medications, and preparing i.v. solutions for chemotherapy, which include the aseptic mixing of antineoplastic agents, collecting and providing drug information, managing therapeutic drug monitoring, checking treatment regimens for each patient’s chemotherapy, and providing pharmaceutical management and counseling.
Our department reviews the drugs taken by patients before and during their hospitalization. For inpatient care, our department assigns pharmacists to provide medication counseling and drug information for healthcare providers and patients, to pursue effective pharmaceutical care. For outpatient care, our department provides a pharmacy outpatient service, in which pharmacists check patients for adverse reactions and doses of antineoplastic agents, particularly for oral anticancer medications. We assess the necessity of supportive care medications and coordinate with physicians. The pharmacy outpatient service also reviews the drugs taken by all patients to assess the optimal time for them to stop their anticoagulants before their surgery or stop taking metformin before examinations with iodinated contrast material. Pharmacists are on duty at the Outpatient Chemotherapy Center as dedicated staff members. The pharmacists provide a Chemotherapy Hotline Service, which is a direct line for our outpatients who have any problems concerning their chemotherapy treatment. In the Outpatient Chemotherapy Center, pharmacists are always available to provide drug information for healthcare providers and patients. We also provide treatment information to the patient's community pharmacy so that we can provide seamless pharmaceutical care. We also manage investigational drugs.
Research Activities
We have presented oral sessions and poster sessions 21 times at national and international academic conferences. Seven scientific papers were accepted for publication.
List of papers published in 2023
Journal
1. Uozumi S, Enokida T, Suzuki S, Nishizawa A, Kamata H, Okano T, Kawasaki T, Fujisawa T, Ueda Y, Okano S, Tahara M, Yamaguchi M. Efficacy and safety of adapalene gel as a reactive treatment for cetuximab-induced skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck: A historical cohort comparison study. Journal of oncology pharmacy practice, 30:295-303, 2024
2. Okunaka M, Kotani D, Fujiwara H, Sato K, Fujiwara N, Mishima S, Sakashita S, Yoshino T, Fujita T, Kojima T. Prognosis of patients with residual pathological disease after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy and surgery for esophageal squamous cell carcinoma: a retrospective cohort study. Therapeutic advances in medical oncology, 16:17588359241229432, 2024
3. Okunaka M, Kotani D, Mishima S, Nakamura M, Kawazoe A, Bando H, Yoshino T, Shitara K. Potential Efficacy of Shiunko for Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody-Induced Skin Fissure: A Single Institutional Case Series. Integrative cancer therapies, 23:15347354231225962, 2024
4. Tsuno T, Kawaguchi T, Yanaizumi R, Kondo J, Kojima K, Igarashi T, Inoue M, Miura T, Miyasato A, Azuma K, Hamada H, Saeki T, Mawatari H, Ogura H, Kotani A, Yamaguchi T, Hakamata H. Psychological Barriers to the Use of Opioid Analgesics for Treating Pain in Patients With Advanced Recurrent Cancer: A Multicenter Cohort Study. Palliative medicine reports, 5:43-52, 2024
5. Maezawa T, Yonemura M, Baba K, Takeuchi H, Hioki M, Nishimura A, Minatogawa H, Utano T, Amino K, Ito M, Akita N, Iwatani T, Suzuki N. Current Status and Issues of Collaboration Between Physicians and Pharmacists in Fertility Preservation. Journal of adolescent and young adult oncology, 2024
6. Tashiro R, Kawazoe H, Mamishin K, Seto K, Udagawa R, Saito Y, Hashimoto H, Shimoi T, Yonemori K, Yonemura M, Terakado H, Nishimura T, Kawasaki T, Furukawa T, Nakamura T. Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study. Scientific reports, 13:11962, 2023
7. Shinozaki T, Imai T, Kobayashi K, Yoshimoto S, Zenda S, Yamaguchi T, Eguchi K, Okano T, Mashiko T, Kurosaki M, Miyaji T, Matsuura K. Preoperative steroid for enhancing patients' recovery after head and neck cancer surgery with free tissue transfer reconstruction: protocol for a phase III, placebo-controlled, randomised, double-blind study (J-SUPPORT 2022, PreSte-HN Study). BMJ open, 13:e069303, 2023
8. Shibutani Y, Tajiri K, Suzuki S, Enokida T, Sagara A, Okano S, Fujisawa T, Sato F, Yumoto T, Sano M, Kawasaki T, Tahara M. Association between baseline blood pressure and the incidence of lenvatinib-induced hypertension in patients with thyroid cancer. Cancer medicine, 12:20773-20782, 2023
9. Baba K, Kawamoto M, Mamishin K, Uematsu M, Kiyohara H, Hirota A, Takahashi N, Fukuda M, Kusuhara S, Nakajima H, Funasaka C, Nakao T, Kondoh C, Harano K, Matsubara N, Naito Y, Hosono A, Kawasaki T, Mukohara T. The impact of the COVID-19 pandemic on perioperative chemotherapy for breast cancer. Cancer medicine, 12:12095-12105, 2023
10. Nakamura H, Kawazoe A, Okunaka M, Demachi K, Kotani D, Shitara K. Safety and Efficacy of Trifluridine/Tipiracil Administered After Anti-PD-1 Therapies for Advanced Gastric Cancer. In vivo (Athens, Greece), 37:1729-1734, 2023
11. Okunaka M, Kawazoe A, Nakamura H, Kotani D, Mishima S, Kuboki Y, Nakamura Y, Shitara K. Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience. Gastric cancer, 26:1030-1039, 2023